Astellas Pharma Inc R&D Meeting Transcript
[Interpreted] Yes. Good afternoon. I'm Yasukawa. Despite your busy schedule toward the end of the year, thank you very much for joining our R&D Meeting. The topic, as was mentioned, is the progress of the focus area approach. Recently, we received questions that 2027 and beyond, the Astellas' strategy is not well known. So please explain that. And also, the 6 -- or the [7] inclusive of [83 72], we really do not know those products beyond those 7 . So to answer those questions, we would talk about the primary focus approach. Therefore, our primary focus lead has prepared the meeting -- prepared the presentations to this end.
And also the value of our pipeline and also the value of the technology platform that support our value, that should be recognized by all the stakeholders. So through this, we have the opportunities to collaborate with the academia, other companies and also by combining our strengths, we'll be able to reach the win-win situation for the partners. So in that sense, the Slide 2, primary focus
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
